Virus-based immunotherapies

Transgene designs immunotherapeutics that harness the mechanisms of the immune response to enable the patient’s body to fight against disease.

Transgene uses its acknowledged know-how in genome engineering to design biological products that are capable of inducing an immune response against abnormal cells.

A bit of history

In the 19th century, doctors already noticed that patients affected by certain viral or bacterial infections would see the size or their tumors stabilize or decrease. Until the rise of modern genetics and protein sciences, these findings could not be turned into therapeutics. At that time, it was impossible to optimize these viruses to direct them only against the targeted disease.

Transgene

Our name stands for one of our key know-how, integrating genetic sequences (or transgenes) into viral vectors to transform them into weapons that can directly or indirectly killing abnormal cells.

Our leading-edge technology is based on a multidisciplinary team, an acknowledged know-how and a large patent portfolio.

Therapeutic Vaccines

Therapeutic vaccines are active and targeted immunotherapeutics. They induce a cascade of immune reactions that lead to the production of T cells that will only destroy specific malignant cells.

Clinical trials evaluating our products are ongoing. Their safety profile and first efficacy data make them promising drug candidates.

Our portfolio comprises two clinical-stage therapeutic vaccines.

TG4001

TG4001 – HPV-positive cancers

TG4050

TG4050 – ovarian cancer and head & neck cancers

Oncolytic viruses

With its oncolytic viruses, Transgene attacks tumors on several fronts. Oncolytics selectively multiply in cancer cells (a process called cell lysis) and indirectly trigger the activation of the immune system against the tumor.

Transgene believes that oncolytic viruses, by integrating complimentary mechanisms of action, can become an efficacious therapy for multiple cancers.

Two oncolytic viruses are currently being developed in the clinic.

TG6002

TG6002 – colorectal cancer

Anti-CTLA-4

BT-001 (VV GM-CSF Anti-CTLA-4) – solid tumors

Individualized immunotherapy:

one patient, one cancer, one vaccine

myvac®

myvac®

With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform. Our approach is based on the Modified Vaccinia Ankara (MVA) viral vector, which has already been validated in clinical trials. myvac® is designed to stimulate and educate the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations. The neoantigens, which are the basis for the myvac® approach, are identified by sequencing and selected using artificial intelligence algorithms, and then integrated into the genome of the viral vector. Once administered to the patient, myvac® triggers a cascade of immune responses against a variety of targets found in the cancer cells.

To create this promising treatment, Transgene has set up an innovative network that covers bioengineering, digital transformation, genomics, translational data, and our established vectorization know-how. Together, NEC, Institut Curie, HalioDx, Traaser and Transgene have tackled and overcome scientific and technical challenges. Transgene has also set up a unique in-house GMP production unit.

Transgene has been awarded an “Investments for the Future” funding from Bpifrance for the development of its platform myvac®.

TG4050 is the first myvac® product candidate . It is codeveloped with NEC. TG4050 is being evaluated in two Phase 1 clinical trials for the treatment of ovarian cancer and head and neck cancers.

Publications myvac®

See all publications

Multifunctional oncolytic viruses:

a new generation of products

Invir. IO

Our proprietary oncolytic virus (OV) platform Invir.IO allows us to design a new generation of immunotherapy. These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.

Our patented technology can generate oncolytic viruses armed with anticancer weapons that combine several mechanisms of action. They activate the immune system, replicate within cancers causing cell lysis (breakdown), and can express their anticancer weapon into the tumor where it will be active.

To design these multifunctional viruses, Transgene capitalizes on its expertise in viral vector engineering and can also rely on collaborations. Our patented technology has already generated several drug candidates undergoing preclinical evaluation.

The first Invir.IO™ oncolytic virus (BT-001) is armed with an anti-CTLA4 antibody; it is codeveloped with BioInvent and could enter the clinic in 2020.

Also, Transgene and AstraZeneca signed a collaborative research agreement to co-develop five multi-armed oncolytic viruses from the Invir.IO™ platform.

The ­ first Invir.IO™ oncolytic virus is expected to enter the clinic in 2020.

Publications on Invir.IO™

See all publications

Publications